XLO FY 2021 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$29M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$1M

Operating Income

-$75M

Net Income

-$76M

EPS (Diluted)

$-2.72

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$82M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$222M

Total Liabilities

$36M

Stockholders' Equity

$185M

Cash & Equivalents

$198M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$1M	-$1M	-40.8%
Operating Income	-$75M	-$55M	-37.5%
Net Income	-$76M	-$55M	-37.3%